In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that grew on EGFR pills went a median 8.3 months without progression on ruzaltatug rezetecan,…
In a phase 3 trial published Oct. 26, 2026, in The Lancet, women with HR+/HER2- breast cancer that had progressed after hormone therapy, CDK4/6 inhibitors and chemotherapy went a median 8.2 months…
In a phase 3 trial published Oct. 26, 2026, in The Lancet, people with EGFR lung cancer that had grown on third-generation EGFR pills went a median 11.1 months without progression on…
